Skip to main content

Table 4 Case-control comparison of NAT1 genotypes

From: Polymorphic genes of detoxification and mitochondrial enzymes and risk for progressive supranuclear palsy: a case control study

  Controls(N = 426) Cases (N = 545)    
NAT1 Genotype n % n % OR CI p
NAT1*4/*4 211 50.8 268 49.7 1   
NAT1*10/*11A 4 1.0 5 0.9 1.03 0.26-4.35 0.967
NAT1*10/*10 14 3.4 22 4.1 1.22 0.61-2.52 0.583
NAT1*4/*3 13 3.1 23 4.3 1.50 0.74-3.14 0.271
NAT1*4/*14A or *10/*14B 13 3.1 19 3.5 1.25 0.60-2.66 0.552
NAT1*10/*14A 4 1.0 6 1.1 1.12 0.31-4.45 0.863
NAT1*4/*10 138 33.3 165 30.6 0.94 0.70-1.26 0.677
NAT1*4/*11A or *3/*11B 13 3.1 21 3.9 1.21 0.59-2.55 0.607
NAT1*10/*15 0 0.0 1 0.2 -- -- --
NAT1*11A/*14A 0 0.0 1 0.2 -- -- --
NAT1*3/*10 2 0.5 4 0.7 1.65 0.32-12.10 0.567
NAT1*3/*14A 0 0.0 1 0.2 -- -- --
NAT1*4/*11B 0 0.0 1 0.2 -- -- --
NAT1*4/*15 3 0.7 2 0.4 0.37 0.05-2.39 0.298
Missing 11   6     
  1. Logistic regression analysis of individual NAT1 genotypes, adjusted for age. NAT1*4/*4 used as reference. Overall chi-squared p = 0.99 (likelihood ratio test). Genotypes with 10 or less counts in either group (case or control) were not included in overall test of significance. OR = odds ratio, CI = 95% confidence intervals for ORs, p = p-value